Table 3.
The top-10% ranked pathways (31/319) that are visited in the use case of IPF
| Rank | Pathway name | Score |
|---|---|---|
| 1 | MAPK-signaling pathway | 19 325 |
| 2 | Toll-like receptor-signaling pathway | 6517 |
| 3 | Cytokine–cytokine receptor interaction | 5569 |
| 4 | Pathways in cancer | 3826 |
| 5 | TGF-beta signaling pathway | 2889 |
| 6 | Chemokine-signaling pathway | 2095 |
| 7 | PI3K-Akt-signaling pathway | 1974 |
| 8 | AGE-RAGE-signaling pathway in diabetic complications | 1974 |
| 9 | Malaria | 1903 |
| 10 | TNF-signaling pathway | 1900 |
| 11 | Endocytosis | 1692 |
| 12 | Apoptosis | 1508 |
| 13 | NF-kappa B-signaling pathway | 1471 |
| 14 | African trypanosomiasis | 1466 |
| 15 | Rheumatoid arthritis | 1451 |
| 16 | Melanoma | 1442 |
| 17 | Chagas disease (American trypanosomiasis) | 1298 |
| 18 | Pertussis | 1260 |
| 19 | Gap junction | 1209 |
| 20 | IL-17-signaling pathway | 1194 |
| 21 | Hippo-signaling pathway | 1137 |
| 22 | Calcium-signaling pathway | 1096 |
| 23 | Apelin-signaling pathway | 1060 |
| 24 | Epithelial cell signaling in Helicobacter pylori infection | 1012 |
| 25 | Fluid shear stress and atherosclerosis | 978 |
| 26 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 953 |
| 27 | Osteoclast differentiation | 949 |
| 28 | Inflammatory bowel disease | 949 |
| 29 | Gastric cancer | 944 |
| 30 | EGFR tyrosine kinase inhibitor resistance | 938 |
| 31 | Adherens junction | 931 |
Note: The score denotes the times a pathway participated in the shortest path that was traversed by the random walker.